Athersys (NASDAQ:ATHX) Coverage Initiated at StockNews.com

Analysts at StockNews.com started coverage on shares of Athersys (NASDAQ:ATHX) in a note issued to investors on Saturday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Athersys Stock Performance

The company has a market cap of $833,000.00, a price-to-earnings ratio of -0.01 and a beta of -0.90. Athersys has a 1 year low of $0.01 and a 1 year high of $1.99.

About Athersys

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.